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Introduction
The calcium-sensing receptor (CaSR) gene plays an important role in calcium 
metabolism. Activating mutations of the CaSR gene are responsible for autosomal 
dominant hypocalcaemia, which is a rare disease characterised by hypocalcaemia, 
hypoparathyroidism, and hypercalciuria. A positive family history is clear for most patients, 
but de-novo mutations should be suspected for those patients without autosomal 
dominant inheritance. 
Case report
A 6-year-old girl first presented in November 2005 with a generalised tonic-clonic seizure 
(for a few minutes) associated with upper respiratory tract infection. Her birth history was 
uneventful, and she lived in China until the age of 6 years. Her medical history revealed 
that she had several episodes of febrile convulsions with admissions to hospitals in 
China since the age of 1 year. The seizures were brief and no further investigations were 
performed. Apart from the episodes of febrile convulsions, she had no relevant history. 
At physical examination, she had normal growth parameters and there were no obvious 
congenital anomalies. Neurological examination was normal. 
 Laboratory evaluation showed hypocalcaemia level of 1.56 mmol/L (reference range, 
2.10-2.65 mmol/L) and hyperphosphataemia level of 3.12 mmol/L (0.82-1.40 mmol/L). Her 
serum sodium and potassium levels were normal. Her serum parathyroid hormone (PTH) 
level was suppressed to 1.2 pmol/L (reference range, 1.6-6.9 pmol/L), magnesium level was 
mildly decreased to 0.62 mmol/L (0.66-0.95 mmol/L), and 25-hydroxyvitamin D level was 
normal. Urinary calcium-to-creatinine ratio (UCa/Cr) was 0.41 mmol/mmol. Computed 
tomographic scan of the brain revealed calcification at the basal ganglia (Fig). Ultrasound 
scan of the kidney showed no nephrocalcinosis. Electrocardiogram and echocardiogram 
were normal. 22q11 microdeletion was excluded by fluorescence in-situ hybridisation 
analysis. There was no history of hypocalcaemia in either side of the family, and both 
parents had normal serum calcium levels.
 She was initially diagnosed as having idiopathic hypoparathyroidism and mild 
hypomagnesaemia. Calcitriol, calcium, and magnesium supplements were started at the 
age of 6 years. The medications were titrated according to the serum calcium level and 
were aimed at keeping the serum calcium at the lower limit of normal. In the following 
few years, the serum magnesium level was normalised with low-dose magnesium 
supplements. However, the serum calcium was difficult to maintain near the target level 
despite treatment with high-dose calcitriol (1 µg/day) and calcium supplements (elemental 
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A significant proportion of patients formerly diagnosed with idiopathic hypoparathyroidism 
actually have activating mutation of the calcium-sensing receptor (CaSR) gene. Awareness 
of the possibility of activating mutation of CaSR gene in patients with sporadic idiopathic 
hypoparathyroidism is important because of its relevance to clinical management. This 
report is of a novel activating mutation of the CaSR gene identified in a 10-year-old Chinese 
girl who was initially diagnosed as having idiopathic hypoparathyroidism at 6 years of age 
after presenting with seizures. Her serum calcium level was difficult to maintain near the 
lower limit of normal despite treatment with high-dose calcitriol. Treatment with calcitriol 
produced significantly elevated urinary calcium-to-creatinine ratio. Direct sequencing of 
the CaSR gene showed a novel heterozygous mutation (p.Q735P (c.2204A>C)). Molecular 
genetic analysis of her parents demonstrated that both parents did not harbour the child’s 
mutation, indicating that her mutation had arisen de novo. 
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that her mutation had arisen de novo. 
 Based on the diagnosis of activating mutation 
of the CaSR gene and the high risk of ongoing 
nephrocalcinosis, calcitriol was tapered off. Treatment 
with the thiazide diuretic hydrochlorothiazide was 
initiated at the age of 10 years. Her UCa/Cr decreased 
to 0.3-0.5 mmol/mmol. Although the patient is 
still hypocalcaemic, with serum calcium level 
ranging from 1.62 to 1.75 mmol/L, she is currently 
asymptomatic, which may reflect a chronic clinical 
adaptation to the low serum calcium level.
Discussion
Historically, hypoparathyroidism of unknown aetiology 
has been called idiopathic hypoparathyroidism. 
However, a significant proportion of patients, perhaps 
as many as one-third, previously diagnosed with 
idiopathic hypoparathyroidism may have activating 
mutations in the CaSR gene.2 
 CaSR is a member of the heptahelical G protein–
coupled receptors that is highly expressed in the 
parathyroid glands and kidneys. Cloning of the CaSR 
gene is located on chromosome 3p13 and it plays an 
important role in calcium homeostasis. Activating 
mutations lower the set point for maintenance of 
serum calcium concentration by inhibition of PTH 
secretion, as well as enhancing renal calcium and 
magnesium excretion, leading to hypoparathyroidism, 
hypocalcaemia, and hypomagnesaemia. Pollak et 
al3 first reported the activating mutation E127A in 
patients with familial hypoparathyroidism in 1994. To 
date, more than 80 activating mutations in the CaSR 
gene have been reported. Although patients with 
activating mutations of the CaSR gene usually have 
a familial occurrence of the disease, sporadic forms 
have been reported.4
 In patients with activating mutation of CaSR, 
the age of onset of symptoms ranges from infancy 
to adulthood. Although there is considerable 
heterogeneity in the severity of the hypocalcaemia 
caused by activating mutation of CaSR, most patients 
with activating mutation of CaSR are asymptomatic; 
some patients however, especially children during 
febrile episodes, can exhibit neuromuscular 
irritability and seizures.2,5 
 Distinguishing activating mutation of CaSR from 
idiopathic hypoparathyroidism can be challenging 
in the clinical setting. One important feature of 
this disorder is the presence of an inappropriately 
high rate of urinary calcium excretion, regardless 
of the presence of hypocalcaemia. Yamamoto et al6 
have shown that the pretreatment mean UCa/Cr 
was significantly higher in patients with activating 
mutation of CaSR when compared with sporadic 
idiopathic hypoparathyroidism. Inhibition of PTH 
secretion in activating mutation of CaSR is the first 
以往被診斷為特發性副甲狀腺機能減退症的病人中，部分其實是由於
鈣離子感應接受器（CaSR）的基因產生活化性突變而引起。由於兩
者的治療方向及目標有所不同，及早發現CaSR的基因活化性變異便
顯得十分重要。本文報告一名10歲華籍女孩在4年前被診斷特發性副
甲狀腺機能減退症，儘管她已被處方高劑量活性維他命D3及鈣補充
劑，其血清鈣濃度仍一直無法維持接近正常下限的水平。另一方面，
尿鈣過高的水平卻逐漸提高。基因序列分析發現CaSR基因第735號密
碼子的第2204個核苷酸出現新型錯義突變。病童的父母並沒有出現相
應的基因變異，所以斷定這病童的基因變異是原發的。
一名華籍女孩因新型原發性鈣離子感應接受
器基因變異而出現持續性低鈣血症
calcium 40 mg/kg/day), and this treatment produced 
a considerably elevated UCa/Cr. When her serum 
calcium levels were between 1.5 and 1.7 mmol/L, the 
UCa/Cr was 1.2 to 3.2 mmol/mmol.
 The persistently high urinary calcium excretion 
despite the coexistence of hypocalcaemia led to 
suspicion of an activating mutation of CaSR. Informed 
consent was obtained from her parents, and genetic 
analysis was performed with genomic DNA extracted 
from peripheral whole blood. DNA fragments from 
the CaSR gene were amplified by polymerase chain 
reaction and the products were sequenced by 
direct DNA sequencing.1 The results showed that 
the patient was heterozygous for a novel mutation 
(p.Q735P (c.2204A>C)) in the CaSR gene. This was a 
missense mutation from A to C in the nucleotide 2204 
of codon 735, leading to gain-of-function of the CaSR. 
Molecular genetic analysis demonstrated that neither 
of her parents harboured this mutation, indicating 
FIG. Computed tomographic scan of the brain showing 
calcification at the bilateral basal ganglia in a 6-year-old girl
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mechanism. The second mechanism is that the 
activating mutation of CaSR, expressed at the thick 
ascending limb of the loop of Henle in the kidney, 
inhibits calcium reabsorption in addition to the 
diminished PTH secretion from the parathyroid 
gland. Hypomagnesaemia is another characteristic 
finding in activating mutation of CaSR. In a meta-
analysis of 38 patients with activating mutation of 
CaSR, 71% had serum magnesium levels of lower 
than 0.7 mmol/L.7 Gunn and Gaffney7 suggested that 
a serum magnesium level of lower than 0.7 mmol/L, 
a PTH level between 1.0 and 3.5 pmol/L, and a 
pretreatment UCa/Cr of higher than 0.30 mmol/mmol 
are all suggestive of a CaSR gene mutation.
 However, the only way to accurately make 
the diagnosis is by genetic analysis, especially 
in the absence of a positive family history. The 
differentiation of activating mutation of the CaSR 
gene and sporadic idiopathic hypoparathyroidism 
is important because patients with the former are at 
greater risk of nephrolithiasis and nephrocalcinosis, 
especially after therapy with 1,25-dihydroxyvitamin 
D3. Rates of nephrocalcinosis in patients with 
activating mutation of CaSR have been reported to 
be between 38% and 57%.2,8
 Given that patients with hypoparathyroidism 
are normally treated with calcium and calcitriol, it is 
important to note that it is not easy to normalise the 
serum calcium level in activating mutation of CaSR 
even with high-dose 1,25-dihydroxyvitamin D3. On 
the other hand, severe renal calcium wasting can 
worsen with calcitriol treatment. Furthermore, one 
study even showed that the expression of the CaSR 
gene may be upregulated by 1,25-dihydroxyvitamin 
D in the parathyroid glands and renal tubules.9 
Hence, treatment with calcitriol and calcium may 
stimulate excessive calcium excretion because 
of increased expression of activated CaSR in the 
nephrons, potentially further increasing the risk of 
nephrocalcinosis. Thus, care should be exercised 
to avoid overtreatment of these patients with 
1,25-dihydroxyvitamin D3 or calcium supplements. 
Asymptomatic patients with activating mutation of 
CaSR should not be routinely treated with calcitriol, 
which should be reserved for symptomatic patients. 
The goal should be to increase the serum calcium 
concentration only to a level sufficient to render the 
patient asymptomatic and not necessarily to a normal 
level.5
 Thiazide diuretics, which can lower urinary 
calcium excretion at any given level of serum calcium, 
should be considered for the treatment of patients 
with activating mutation of CaSR. The hypocalciuric 
action of thiazide diuretics has been successfully 
proven for the treatment of idiopathic hypercalciuria 
in children.10 Sato et al11 showed that thiazide 
diuretics have been successfully used to reduce 
urinary calcium excretion and enable reduction of 
the dose of 1,25-dihydroxyvitamin D3 in children with 
activating mutation of CaSR. 
 Parathyroid hormone replacement is a logical 
treatment for this disorder because PTH plays a 
central role in calcium regulation. Mittelman et al12 
demonstrated that treatment with recombinant 
human PTH can maintain a serum calcium level close 
to the lower end of normal while lowering urinary 
calcium excretion in a child with activating mutation 
of CaSR. However, there is still little experience of the 
use of recombinant human PTH in children. Further 
studies evaluating the long-term safety and efficacy 
of PTH in children with activating mutation of CaSR 
are warranted.
Conclusion
This report illustrated that de-novo activating 
mutation of the CaSR gene should be 
suspected in children with sporadic idiopathic 
hypoparathyroidism. Genetic analysis should be 
considered for patients who have hypocalcaemia, 
hypoparathyroidism, and hypercalciuria. Due to the 
high risk of nephrocalcinosis, asymptomatic patients 
with CaSR mutation should not be routinely treated 
with calcitriol. Thiazide diuretics will reduce urinary 
calcium excretion and may allow serum calcium to 
be maintained at reasonable levels without incurring 
undue hypercalciuria.
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